The risk or severity of myelosuppression can be increased when Metamizole is combined with Gemtuzumab ozogamicin. The risk or severity of adverse effects can be increased when Metamizole is combined with Anecortave. Metamizole may increase the neuroexcitatory activities of Fleroxacin. Metamizole may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Metamizole may increase the anticoagulant activities of Protein S human. Sodium phosphate may increase the nephrotoxic activities of Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with 16-Bromoepiandrosterone. The risk or severity of myelosuppression can be increased when Metamizole is combined with Tofacitinib. Metamizole may increase the anticoagulant activities of Danaparoid. The risk or severity of myelosuppression can be increased when Metamizole is combined with Sorafenib. The risk or severity of adverse effects can be increased when Metamizole is combined with Mometasone. Metamizole may decrease the excretion rate of Apramycin which could result in a higher serum level. The risk or severity of myelosuppression can be increased when Metamizole is combined with Vindesine. The risk or severity of myelosuppression can be increased when Metamizole is combined with Ruxolitinib. The risk or severity of myelosuppression can be increased when Metamizole is combined with Streptozocin. The risk or severity of adverse effects can be increased when Imidapril is combined with Metamizole. The risk or severity of myelosuppression can be increased when Metamizole is combined with Vorinostat. The risk or severity of adverse effects can be increased when Cilazapril is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Flumethasone. The risk or severity of adverse effects can be increased when Metamizole is combined with Deferasirox. The risk or severity of myelosuppression can be increased when Metamizole is combined with Etoposide. The risk or severity of myelosuppression can be increased when Metamizole is combined with Cytarabine. The risk or severity of myelosuppression can be increased when Metamizole is combined with Cyclophosphamide. The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Metamizole. The risk or severity of adverse effects can be increased when Indomethacin is combined with Metamizole. The risk or severity of adverse effects can be increased when Nepafenac is combined with Metamizole. Metamizole may decrease the antihypertensive activities of Acebutolol. The risk or severity of myelosuppression can be increased when Metamizole is combined with Ibrutinib. The risk or severity of adverse effects can be increased when Salicylic acid is combined with Metamizole. Metamizole may decrease the antihypertensive activities of Labetalol. Metamizole may decrease the excretion rate of Tobramycin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Valdecoxib is combined with Metamizole. The risk or severity of myelosuppression can be increased when Metamizole is combined with Temsirolimus. The risk or severity of myelosuppression can be increased when Metamizole is combined with Nelarabine. The risk or severity of adverse effects can be increased when Metamizole is combined with Betamethasone. The risk or severity of adverse effects can be increased when Metamizole is combined with Salicylamide. The risk or severity of myelosuppression can be increased when Metamizole is combined with Carbamazepine. The risk or severity of myelosuppression can be increased when Metamizole is combined with Linezolid. The risk or severity of myelosuppression can be increased when Metamizole is combined with Daunorubicin. The risk or severity of adverse effects can be increased when Enalapril is combined with Metamizole. The risk or severity of adverse effects can be increased when Spirapril is combined with Metamizole. The risk or severity of adverse effects can be increased when Ibuprofen is combined with Metamizole. The risk or severity of adverse effects can be increased when Saprisartan is combined with Metamizole. The risk or severity of adverse effects can be increased when Nimesulide is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Ulobetasol. The risk or severity of adverse effects can be increased when Metamizole is combined with Alclofenac. The risk or severity of adverse effects can be increased when Trandolapril is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Omacetaxine mepesuccinate. Metamizole may increase the neuroexcitatory activities of Pazufloxacin. Metamizole may increase the anticoagulant activities of Bivalirudin. The risk or severity of myelosuppression can be increased when Metamizole is combined with Azacitidine. The risk or severity of adverse effects can be increased when Metamizole is combined with Clocortolone. The risk or severity of myelosuppression can be increased when Metamizole is combined with Interferon alfa-n3. The risk or severity of myelosuppression can be increased when Metamizole is combined with Oxaliplatin. The risk or severity of adverse effects can be increased when Metamizole is combined with Aldosterone. Cholestyramine can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Metamizole is combined with NCX 1022. Metamizole may increase the nephrotoxic activities of Tacrolimus. Metamizole may increase the anticoagulant activities of Dabigatran etexilate. The risk or severity of adverse effects can be increased when Telmisartan is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with HE3286. The risk or severity of myelosuppression can be increased when Metamizole is combined with Methimazole. The risk or severity of adverse effects can be increased when Metamizole is combined with Halcinonide. The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Metamizole. Metamizole may decrease the antihypertensive activities of Timolol. Metamizole may decrease the antihypertensive activities of Amiloride. The risk or severity of adverse effects can be increased when Naproxen is combined with Metamizole. Metamizole may decrease the excretion rate of Netilmicin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Metamizole is combined with Beclomethasone dipropionate. The risk or severity of adverse effects can be increased when Metamizole is combined with Flunisolide. Metamizole may decrease the antihypertensive activities of Sotalol. The risk or severity of myelosuppression can be increased when Metamizole is combined with L-Phenylalanine. The risk or severity of myelosuppression can be increased when Metamizole is combined with Olaparib. The risk or severity of myelosuppression can be increased when Metamizole is combined with Vinblastine. The risk or severity of adverse effects can be increased when Salsalate is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Equilenin. The risk or severity of adverse effects can be increased when Metamizole is combined with Androstenedione. Metamizole may decrease the antihypertensive activities of Talinolol. Metamizole may increase the anticoagulant activities of Fluindione. The risk or severity of adverse effects can be increased when Metamizole is combined with Fluprednidene. The risk or severity of adverse effects can be increased when Tasosartan is combined with Metamizole. The risk or severity of myelosuppression can be increased when Metamizole is combined with Vinorelbine. The risk or severity of adverse effects can be increased when Suprofen is combined with Metamizole. Metamizole may decrease the diuretic activities of Bumetanide. The risk or severity of adverse effects can be increased when Metamizole is combined with Difluocortolone. The risk or severity of adverse effects can be increased when Metamizole is combined with Tenofovir disoproxil. The risk or severity of myelosuppression can be increased when Metamizole is combined with Fluorouracil. The therapeutic efficacy of Tafluprost can be decreased when used in combination with Metamizole. The risk or severity of adverse effects can be increased when Moexipril is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Prasterone. The risk or severity of adverse effects can be increased when Metamizole is combined with Carbaspirin calcium. Metamizole may increase the anticoagulant activities of Ximelagatran. The risk or severity of adverse effects can be increased when Metamizole is combined with Isoxicam. The risk or severity of myelosuppression can be increased when Metamizole is combined with Irinotecan. Metamizole may decrease the excretion rate of Aclarubicin which could result in a higher serum level. Metamizole may decrease the antihypertensive activities of Carvedilol. Metamizole may decrease the excretion rate of Paromomycin which could result in a higher serum level. Metamizole may increase the anticoagulant activities of Dicoumarol. The risk or severity of adverse effects can be increased when Diclofenac is combined with Metamizole. The risk or severity of adverse effects can be increased when Sulindac is combined with Metamizole. The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Fenbufen. The risk or severity of myelosuppression can be increased when Metamizole is combined with Bosutinib. Sarilumab may increase the immunosuppressive activities of Metamizole. Metamizole may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Metamizole is combined with Semapimod. Metamizole may decrease the antihypertensive activities of Bucindolol. The risk or severity of adverse effects can be increased when Zofenopril is combined with Metamizole. The risk or severity of adverse effects can be increased when Candoxatril is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Haloperidol. Metamizole may increase the neuroexcitatory activities of Pefloxacin. Metamizole may decrease the excretion rate of Metrizamide which could result in a higher serum level. The risk or severity of myelosuppression can be increased when Metamizole is combined with Eribulin. The risk or severity of adverse effects can be increased when Metamizole is combined with Desonide. The risk or severity of myelosuppression can be increased when Metamizole is combined with Alemtuzumab. The risk or severity of myelosuppression can be increased when Metamizole is combined with Blinatumomab. The risk or severity of myelosuppression can be increased when Metamizole is combined with Dactinomycin. The risk or severity of adverse effects can be increased when Metamizole is combined with Prednicarbate. Metamizole may increase the neuroexcitatory activities of Cinoxacin. The risk or severity of adverse effects can be increased when Metamizole is combined with Amcinonide. The risk or severity of myelosuppression can be increased when Metamizole is combined with Doxorubicin. The risk or severity of adverse effects can be increased when Metamizole is combined with Cortisone acetate. The risk or severity of adverse effects can be increased when Metamizole is combined with Apremilast. Metamizole may increase the anticoagulant activities of Darexaban. Metamizole may decrease the antihypertensive activities of Spironolactone. Metamizole may decrease the antihypertensive activities of Propranolol. The risk or severity of myelosuppression can be increased when Metamizole is combined with Capecitabine. Metamizole may decrease the antihypertensive activities of Esmolol. The risk or severity of adverse effects can be increased when Metamizole is combined with Zaltoprofen. The serum concentration of Vancomycin can be increased when it is combined with Metamizole.